Korean J Pediatr Hematol Oncol.
2003 Oct;10(2):206-213.
Effect of Leukokine in Patients with Acute Leukemia Receiving Induction Chemotherapy
- Affiliations
-
- 1Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea. hakkikim@cmc.cuk.ac.kr
- 2Department of Pediatrics, Kyungpook National University School of Medicine, Daegu, Korea.
- 3Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.
- 4Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
- 5Department of Pediatrics, Chonnam National University Medical School, Gwangju, Korea.
- 6Hematology-Oncology, Department of Internal Medicine, University of Ulsan, Asan Medical Center, Seoul, Korea.
Abstract
- PURPOSE
Neutropenia is common in patients receiving myelotoxic chemotherapy. The aim of this study is to compare the efficacy, safety and adverse events between prophylactically administered Leukokine and Grasin. METHODS: An open-label, randomized, phase III study was designed to compare the effects of a subcutaneous injection of Leukokine (CJ Corp.) 100mug/m2 with Grasin (Jeil Pharm. Inc.) in patients receiving induction chemotherapy for acute leukemia. All patients received one dose of G-CSF every day during the study period. Total period of G-CSF injection was not over 14 days. The administration of G-CSF began on day 14 after beginning of chemotherapy under CCG strategy. In other chemotherapies, the injection of G-CSF started on day 1 from end of chemotherapy. Injection of G-CSF stopped after absolute neutrophil count recovery was achieved. RESULTS: The median numbers of times of administration were 9.6 (2~14) /cycle for Leukokine and 8.8 (2~14) /cycle for Grasin. The time to needed for neutrophil recovery more than 1, 000/mm3 was 6.6 4.9 day and 4.7 4.8 day of the Leukokine and Grasin, respectively (P=0.14). The mean duration of neutropenia less than 500/mm3 was 7.6 5.6 days for Leukokine and 6.1 6.0 days for Grasin (P=0.28). The results for the two groups were also not significantly different in adverse events, physical examination and laboratory findings. CONCLUSION: Leukokine was safe and well tolerated in these patients population. Injection of Leukokine provided neutrophil recovery with safety and efficacy similar to that provided by Grasin.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The Long-term Effect of Induction Chemotherapy with All-trans-retinoic Acid(ATRA) Follwed by Consolidation Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia
- Change of Serum IGF-I and IGFBP-3 Concentration During Induction Chemotherapy in Children with Acute Lymphocytic Leukemia
- A Case of Acute Myelogenous Leukemia during Pregnancy
- Change of Thyroid Function during Chemotherapy in Chilolren with Acute Leukemia
- Fatal Breakthrough Mucormycosis in an Acute Myelogenous Leukemia Patient while on Posaconazole Prophylaxis
